OOIR: Observatory of International Research

Papers

(The H4-Index of Oncologist is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcino	166
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial	100
18 Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model	89
55 Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma	89
Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites	75
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer	75
Calls to action on lung cancer management and research	69
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer	59
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs	57
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study	57
Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary	56
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data	48
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)	46
Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics	46
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis	41
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results	41
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation	38
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer	37
Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review	37
Prevalence ofBRCA1andBRCA2Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer	37
GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1	36
Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes	35
56 Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer	35
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events	33
Correction to: Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)	33

A blueprint for creating an early-onset colorectal cancer program based on experiences from seven clinical centers across the United States and Canada	32
“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management	32
Classification of NK-large granular lymphocytic leukemia by CD56 expression	32
Contextualizing results of randomized trials in smoldering myeloma	32
Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy	32
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy	31
ALK-positive Adult Histiocytosis With a TFG-ALK Fusion Gene: A Case Report	31
Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma	31